Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.264,15 -9,90 (-0,03%) EUR/USD
1,0719 +0,0001 (+0,01%) Bitcoin EUR
53.570,70 -2.638,17 (-4,69%) CMC Crypto 200
1.260,91 -78,16 (-5,84%)
Gilead Sciences, Inc. (0QYQ.IL)
| Chiusura precedente | 65,07 |
| Aperto | 0,00 |
| Denaro | 62,37 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 51.015 |
| Capitalizzazione | 81,464B |
| Beta (5 anni mensile) | 0,35 |
| Rapporto PE (ttm) | 15,03 |
| EPS (ttm) | 4,35 |
| Prossima data utili | 25 apr 2024 |
| Rendimento e dividendo (futuro) | 3,00 (3,81%) |
| Data ex dividendo | 14 set 2023 |
| Stima target 1A | N/D |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireCenter for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr
